Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
J Clin Psychiatry 2008;69:1364-1373
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To evaluate the efficacy and safety of 30, 50, and
70 mg/day lisdexamfetamine dimesylate compared with placebo in adults with
attention-deficit/hyperactivity disorder (ADHD).
Method: Following a 7- to 28-day washout, 420 adults aged 18
to 55 years with moderate to severe ADHD (DSM-IV-TR criteria) were treated with
30, 50, or 70 mg/day lisdexamfetamine or placebo, respectively, for 4 weeks (N
= 119, 117, 122, and 62, respectively). The 50- and 70-mg/day groups underwent
forced-dose titration. The primary efficacy measure was the
clinician-determined ADHD Rating Scale (ADHD-RS) total score. The study was
conducted from May 2006 to November 2006.
Results: Treatment groups were well matched at baseline,
including in ADHD-RS scores. At endpoint, changes in ADHD-RS scores were
significantly greater for each lisdexamfetamine dose than for placebo (placebo
= -8.2, 30 mg/day lisdexamfetamine = -16.2, 50 mg/day lisdexamfetamine = -17.4,
70 mg/day lisdexamfetamine = -18.6; all p < .0001 vs. placebo), with no
differences between doses. Significant differences relative to placebo were
observed in each lisdexamfetamine group, beginning at week 1 and for each week
throughout. The percentage of subjects who improved (Clinical Global
Impressions-Improvement scale rating <= 2) was significantly greater for each
lisdexamfetamine dose than for placebo at each week and at endpoint (placebo =
29%, 30 mg/day lisdexamfetamine = 57%, 50 mg/day lisdexamfetamine = 62%, 70
mg/day lisdexamfetamine = 61%; all p < .01). Adverse events were generally mild
and included dry mouth, decreased appetite, and insomnia.
Conclusion: All 3 lisdexamfetamine doses were significantly
more effective than placebo in the treatment of adults with ADHD, with
improvements noted within 1 week. Lisdexamfetamine was generally well tolerated
by these patients.
Trial Registration: clinicaltrials.gov Identifier: NCT00334880